Skip to main content

Abstract

Surgical resection for pancreatic adenocarcinoma remains the only single modality with the potential for cure or long-term survival. With improvements in surgical techniques and perioperative management, the morbidity and mortality associated with pancreatic resection has significantly improved. Nonetheless, the long-term oncologic outcomes of patients with pancreatic cancer have remained relatively poor despite these advances due to the biological aggressiveness of the disease and its widely disseminated nature at the time of diagnosis. Identification of patient- and tumor-specific risk factors and use of novel resectability classifications have now facilitated prediction of patients who may derive benefit from surgical procedures. Furthermore, significant improvements in the activity of systemic and locoregional therapies has resulted in an increase in the number of patients that may benefit from selectively aggressive operations with the need for more complex vascular procedures to accomplish oncologically effective resections. Any surgeons involved in the operative care of patients with pancreatic cancer should therefore have significant training and experience in these advanced techniques and have a full comprehensive understanding of expected risks and outcomes of such interventions.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Katz MH, Pisters PW, Evans DB, Sun CC, Lee JE, Fleming JB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg. 2008;206(5):833–46; discussion 846–8. Epub 2008/05/13.

    Article  PubMed  Google Scholar 

  2. Varadhachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, Wang H, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006;13(8):1035–46. Epub 2006/07/26.

    Article  PubMed  Google Scholar 

  3. Al-Hawary MM, Francis IR, Chari ST, Fishman EK, Hough DM, Lu DS, et al. Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the Society of Abdominal Radiology and the American Pancreatic Association. Gastroenterology. 2014;146(1):291–304 e1. Epub 2013/12/21.

    Article  PubMed  Google Scholar 

  4. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Pancreatic Adenocarcinoma. Version 2.2012. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed 2012.

  5. Paniccia A, Hosokawa P, Henderson W, Schulick RD, Edil BH, McCarter MD, et al. Characteristics of 10-year survivors of pancreatic ductal adenocarcinoma. JAMA Surg. 2015. doi:10.1001/jamasurg.2015.0668. Epub 2015/06/11.

    Google Scholar 

  6. Schnelldorfer T, Ware AL, Sarr MG, Smyrk TC, Zhang L, Qin R, et al. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg. 2008;247(3):456–62. Epub 2008/04/01.

    Article  PubMed  Google Scholar 

  7. Faisal F, Tsai HL, Blackford A, Olino K, Xia C, De Jesus-Acosta A, et al. (2013). Longer course of induction chemotherapy followed by chemoradiation favors better survival outcomes for patients with locally advanced pancreatic cancer. Am J Clin Oncol 2013;00:000–000.

    Google Scholar 

  8. Huguet F, Andre T, Hammel P, Artru P, Balosso J, Selle F, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol. 2007;25(3):326–31. Epub 2007/01/20.

    Article  CAS  PubMed  Google Scholar 

  9. Ko AH, Quivey JM, Venook AP, Bergsland EK, Dito E, Schillinger B, et al. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2007;68(3):809–16. Epub 2007/03/17.

    Article  CAS  PubMed  Google Scholar 

  10. Crane CH, Varadhachary GR, Javle MM, Safran H, Krishnan S, Fleming JB. Multi-institutional phase II trial of induction cetuximab, gemcitabine, and oxaliplatin, followed by radiotherapy with concurrent capecitabine, and cetuximab, for locally advanced pancreatic adenocarcinoma (LAPC). J Pancreas (Online). 2010;11(2):139–43.

    Google Scholar 

  11. Hsu CC, Herman JM, Corsini MM, Winter JM, Callister MD, Haddock MG, et al. Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol. 2010;17(4):981–90. Epub 2010/01/21.

    Article  PubMed Central  PubMed  Google Scholar 

  12. Winter JM, Cameron JL, Campbell KA, Arnold MA, Chang DC, Coleman J, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg. 2006;10(9):1199–210; discussion 1210–1. Epub 2006/11/23.

    Article  PubMed  Google Scholar 

  13. Haeno H, Gonen M, Davis MB, Herman JM, Iacobuzio-Donahue CA, Michor F. Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell. 2012;148(1–2):362–75. Epub 2012/01/24.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010;467(7319):1114–7. Epub 2010/10/29.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS. National failure to operate on early stage pancreatic cancer. Ann Surg. 2007;246(2):173–80. Epub 2007/08/02.

    Article  PubMed Central  PubMed  Google Scholar 

  16. Iacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, Henderson CM, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 2009;27(11):1806–13. Epub 2009/03/11.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Kamisawa T, Isawa T, Koike M, Tsuruta K, Okamoto A. Hematogenous metastases of pancreatic ductal carcinoma. Pancreas. 1995;11(4):345–9. Epub 1995/11/01.

    Article  CAS  PubMed  Google Scholar 

  18. Mao C, Domenico DR, Kim K, Hanson DJ, Howard JM. Observations on the developmental patterns and the consequences of pancreatic exocrine adenocarcinoma. Findings of 154 autopsies. Arch Surg. 1995;130(2):125–34. Epub 1995/02/01.

    Article  CAS  PubMed  Google Scholar 

  19. Peixoto RD, Speers C, McGahan CE, Renouf DJ, Schaeffer DF, Kennecke HF. Prognostic factors and sites of metastasis in unresectable locally advanced pancreatic cancer. Cancer Med. 2015. doi:10.1002/cam4.459. Epub 2015/04/22.

    Google Scholar 

  20. Butturini G, Stocken DD, Wente MN, Jeekel H, Klinkenbijl JH, Bakkevold KE, et al. Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. Arch Surg. 2008;143(1):75–83; discussion 83. Epub 2008/01/23.

    Article  PubMed  Google Scholar 

  21. Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4(6):567–79. Epub 2001/04/18.

    Article  CAS  PubMed  Google Scholar 

  22. Sugiura T, Uesaka K, Mihara K, Sasaki K, Kanemoto H, Mizuno T, et al. Margin status, recurrence pattern, and prognosis after resection of pancreatic cancer. Surgery. 2013;154(5):1078–86. Epub 2013/08/27.

    Article  PubMed  Google Scholar 

  23. Neoptolemos JP, Stocken DD, Dunn JA, Almond J, Beger HG, Pederzoli P, et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg. 2001;234(6):758–68. Epub 2001/12/01.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Bilimoria KY, Talamonti MS, Sener SF, Bilimoria MM, Stewart AK, Winchester DP, et al. Effect of hospital volume on margin status after pancreaticoduodenectomy for cancer. J Am Coll Surg. 2008;207(4):510–9. Epub 2008/10/18.

    Article  PubMed  Google Scholar 

  25. La Torre M, Nigri G, Ferrari L, Cosenza G, Ravaioli M, Ramacciato G. Hospital volume, margin status, and long-term survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am Surg. 2012;78(2):225–9. Epub 2012/03/01.

    PubMed  Google Scholar 

  26. Verbeke CS. Resection margins and R1 rates in pancreatic cancer—are we there yet? Histopathology. 2008;52(7):787–96. Epub 2007/12/18.

    Article  CAS  PubMed  Google Scholar 

  27. Rau BM, Moritz K, Schuschan S, Alsfasser G, Prall F, Klar E. R1 resection in pancreatic cancer has significant impact on long-term outcome in standardized pathology modified for routine use. Surgery. 2012;152(3 Suppl 1):S103–11. Epub 2012/07/07.

    Article  PubMed  Google Scholar 

  28. Fatima J, Schnelldorfer T, Barton J, Wood CM, Wiste HJ, Smyrk TC, et al. Pancreatoduodenectomy for ductal adenocarcinoma: implications of positive margin on survival. Arch Surg. 2010;145(2):167–72. Epub 2010/02/17.

    Article  PubMed  Google Scholar 

  29. Fortner JG. Regional resection of cancer of the pancreas: a new surgical approach. Surgery. 1973;73(2):307–20. Epub 1973/02/01.

    CAS  PubMed  Google Scholar 

  30. Castleberry AW, White RR, De La Fuente SG, Clary BM, Blazer III DG, McCann RL, et al. The impact of vascular resection on early postoperative outcomes after pancreaticoduodenectomy: an analysis of the American College of Surgeons National Surgical Quality Improvement Program database. Ann Surg Oncol. 2012;19(13):4068–77. Epub 2012/08/31.

    Article  PubMed  Google Scholar 

  31. Yu XZ, Li J, Fu DL, Di Y, Yang F, Hao SJ, et al. Benefit from synchronous portal-superior mesenteric vein resection during pancreaticoduodenectomy for cancer: a meta-analysis. Eur J Surg Oncol. 2014;40(4):371–8. Epub 2014/02/25.

    Article  CAS  PubMed  Google Scholar 

  32. Fuhrman GM, Leach SD, Staley CA, Cusack JC, Charnsangavej C, Cleary KR, et al. Rationale for en bloc vein resection in the treatment of pancreatic adenocarcinoma adherent to the superior mesenteric-portal vein confluence. Pancreatic Tumor Study Group. Ann Surg. 1996;223(2):154–62. Epub 1996/02/01.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  33. Kelly KJ, Winslow E, Kooby D, Lad NL, Parikh AA, Scoggins CR, et al. Vein involvement during pancreaticoduodenectomy: is there a need for redefinition of “borderline resectable disease”? J Gastrointest Surg. 2013;17(7):1209–17; discussion 1217. Epub 2013/04/27.

    Article  PubMed  Google Scholar 

  34. Ravikumar R, Sabin C, Abu Hilal M, Bramhall S, White S, Wigmore S, et al. Portal vein resection in borderline resectable pancreatic cancer: a United Kingdom multicenter study. J Am Coll Surg. 2014;218(3):401–11. Epub 2014/02/04.

    Article  PubMed  Google Scholar 

  35. Murakami Y, Satoi S, Motoi F, Sho M, Kawai M, Matsumoto I, et al. Portal or superior mesenteric vein resection in pancreatoduodenectomy for pancreatic head carcinoma. Br J Surg. 2015;102(7):837–46. Epub 2015/04/17.

    Article  CAS  PubMed  Google Scholar 

  36. Siriwardana HP, Siriwardena AK. Systematic review of outcome of synchronous portal-superior mesenteric vein resection during pancreatectomy for cancer. Br J Surg. 2006;93(6):662–73. Epub 2006/05/17.

    Article  CAS  PubMed  Google Scholar 

  37. Zhou Y, Zhang Z, Liu Y, Li B, Xu D. Pancreatectomy combined with superior mesenteric vein-portal vein resection for pancreatic cancer: a meta-analysis. World J Surg. 2012;36(4):884–91. Epub 2012/02/22.

    Article  PubMed  Google Scholar 

  38. Turrini O, Ewald J, Barbier L, Mokart D, Blache JL, Delpero JR. Should the portal vein be routinely resected during pancreaticoduodenectomy for adenocarcinoma? Ann Surg. 2013;257(4):726–30. Epub 2012/09/13.

    Article  PubMed  Google Scholar 

  39. Tseng JF, Raut CP, Lee JE, Pisters PW, Vauthey JN, Abdalla EK, et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg. 2004;8(8):935–49; discussion 949–50. Epub 2004/12/09.

    Article  PubMed  Google Scholar 

  40. Bockhorn M, Uzunoglu FG, Adham M, Imrie C, Milicevic M, Sandberg AA, et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2014;155(6):977–88. Epub 2014/05/27.

    Article  PubMed  Google Scholar 

  41. Katz MH, Fleming JB, Pisters PW, Lee JE, Evans DB. Anatomy of the superior mesenteric vein with special reference to the surgical management of first-order branch involvement at pancreaticoduodenectomy. Ann Surg. 2008;248(6):1098–102. Epub 2008/12/19.

    Article  PubMed  Google Scholar 

  42. Callery MP, Pratt WB, Kent TS, Chaikof EL, Vollmer Jr CM. A prospectively validated clinical risk score accurately predicts pancreatic fistula after pancreatoduodenectomy. J Am Coll Surg. 2013;216(1):1–14. Epub 2012/11/06.

    Article  PubMed  Google Scholar 

  43. Muller SA, Hartel M, Mehrabi A, Welsch T, Martin DJ, Hinz U, et al. Vascular resection in pancreatic cancer surgery: survival determinants. J Gastrointest Surg. 2009;13(4):784–92. Epub 2009/01/13.

    Article  PubMed  Google Scholar 

  44. Glebova NO, Hicks CW, Piazza KM, Abularrage CJ, Cameron AM, Schulick RD, et al. Technical risk factors for portal vein reconstruction thrombosis in pancreatic resection. J Vasc Surg. 2015. doi:10.1016/j.jvs.2015.01.061. Epub 2015/05/09.

    Google Scholar 

  45. Christians KK, Riggle K, Keim R, Pappas S, Tsai S, Ritch P, et al. Distal splenorenal and temporary mesocaval shunting at the time of pancreatectomy for cancer: initial experience from the Medical College of Wisconsin. Surgery. 2013;154(1):123–31. Epub 2013/01/12.

    Article  PubMed  Google Scholar 

  46. Katz MH, Lee JE, Pisters PW, Skoracki R, Tamm E, Fleming JB. Retroperitoneal dissection in patients with borderline resectable pancreatic cancer: operative principles and techniques. J Am Coll Surg. 2012;215(2):e11–8. Epub 2012/07/24.

    Article  PubMed Central  PubMed  Google Scholar 

  47. Bockhorn M, Burdelski C, Bogoevski D, Sgourakis G, Yekebas EF, Izbicki JR. Arterial en bloc resection for pancreatic carcinoma. Br J Surg. 2011;98(1):86–92. Epub 2010/12/08.

    Article  CAS  PubMed  Google Scholar 

  48. Bachellier P, Rosso E, Lucescu I, Oussoultzoglou E, Tracey J, Pessaux P, et al. Is the need for an arterial resection a contraindication to pancreatic resection for locally advanced pancreatic adenocarcinoma? A case-matched controlled study. J Surg Oncol. 2011;103(1):75–84. Epub 2010/11/26.

    Article  PubMed  Google Scholar 

  49. Mollberg N, Rahbari NN, Koch M, Hartwig W, Hoeger Y, Buchler MW, et al. Arterial resection during pancreatectomy for pancreatic cancer: a systematic review and meta-analysis. Ann Surg. 2011;254(6):882–93. Epub 2011/11/09.

    Article  PubMed  Google Scholar 

  50. Hartwig W, Hackert T, Hinz U, Hassenpflug M, Strobel O, Buchler MW, et al. Multivisceral resection for pancreatic malignancies: risk-analysis and long-term outcome. Ann Surg. 2009;250(1):81–7. Epub 2009/06/30.

    Article  PubMed  Google Scholar 

  51. Shoup M, Conlon KC, Klimstra D, Brennan MF. Is extended resection for adenocarcinoma of the body or tail of the pancreas justified? J Gastrointest Surg. 2003;7(8):946–52; discussion 952. Epub 2003/12/17.

    Article  PubMed  Google Scholar 

  52. Okada K, Kawai M, Tani M, Hirono S, Miyazawa M, Shimizu A, et al. Surgical strategy for patients with pancreatic body/tail carcinoma: who should undergo distal pancreatectomy with en-bloc celiac axis resection? Surgery. 2013;153(3):365–72. Epub 2012/10/11.

    Article  PubMed  Google Scholar 

  53. Hirano S, Kondo S, Hara T, Ambo Y, Tanaka E, Shichinohe T, et al. Distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic body cancer: long-term results. Ann Surg. 2007;246(1):46–51. Epub 2007/06/27.

    Article  PubMed Central  PubMed  Google Scholar 

  54. Kang CM, Kim DH, Choi GH, Kim KS, Choi JS, Lee WJ. Detrimental effect of postoperative complications on oncologic efficacy of R0 pancreatectomy in ductal adenocarcinoma of the pancreas. J Gastrointest Surg. 2009;13(5):907–14. Epub 2009/02/19.

    Article  PubMed  Google Scholar 

  55. Gillen S, Schuster T, Meyer Zum Buschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS medicine. 2010;7(4):e1000267. Epub 2010/04/28.

    Article  PubMed Central  PubMed  Google Scholar 

  56. Chun YS, Milestone BN, Watson JC, Cohen SJ, Burtness B, Engstrom PF, et al. Defining venous involvement in borderline resectable pancreatic cancer. Ann Surg Oncol. 2010;17(11):2832–8. Epub 2010/08/21.

    Article  PubMed  Google Scholar 

  57. Li H, Zeng MS, Zhou KR, Jin DY, Lou WH. Pancreatic adenocarcinoma: the different CT criteria for peripancreatic major arterial and venous invasion. J Comput Assist Tomogr. 2005;29(2):170–5. Epub 2005/03/18.

    Article  PubMed  Google Scholar 

  58. Lu DS, Reber HA, Krasny RM, Kadell BM, Sayre J. Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT. AJR Am J Roentgenol. 1997;168(6):1439–43. Epub 1997/06/01.

    Article  CAS  PubMed  Google Scholar 

  59. Phoa SS, Reeders JW, Stoker J, Rauws EA, Gouma DJ, Lameris JS. CT criteria for venous invasion in patients with pancreatic head carcinoma. Br J Radiol. 2000;73(875):1159–64. Epub 2001/01/06.

    Article  CAS  PubMed  Google Scholar 

  60. Tran Cao HS, Balachandran A, Wang H, Nogueras-Gonzalez GM, Bailey CE, Lee JE, et al. Radiographic tumor-vein interface as a predictor of intraoperative, pathologic, and oncologic outcomes in resectable and borderline resectable pancreatic cancer. J Gastrointest Surg. 2014;18(2):269–78; discussion 278. Epub 2013/10/17.

    Article  PubMed  Google Scholar 

  61. Katz MH, Fleming JB, Bhosale P, Varadhachary G, Lee JE, Wolff R, et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012;118(23):5749–56. Epub 2012/05/19.

    Article  PubMed  Google Scholar 

  62. Cassinotto C, Mouries A, Lafourcade JP, Terrebonne E, Belleannee G, Blanc JF, et al. Locally advanced pancreatic adenocarcinoma: reassessment of response with CT after neoadjuvant chemotherapy and radiation therapy. Radiology. 2014;273(1):108–16. Epub 2014/06/25.

    Article  PubMed  Google Scholar 

  63. Habermehl D, Kessel K, Welzel T, Hof H, Abdollahi A, Bergmann F, et al. Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer. Radiat Oncol. 2012;7:28. Epub 2012/03/06.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  64. Bang S, Chung HW, Park SW, Chung JB, Yun M, Lee JD, et al. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer. J Clin Gastroenterol. 2006;40(10):923–9. Epub 2006/10/26.

    Article  PubMed  Google Scholar 

  65. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25. Epub 2011/05/13.

    Article  CAS  PubMed  Google Scholar 

  66. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–703. Epub 2013/10/18.

    Article  Google Scholar 

  67. Truty MJ, Thomas RM, Katz MH, Vauthey JN, Crane C, Varadhachary GR, et al. Multimodality therapy offers a chance for cure in patients with pancreatic adenocarcinoma deemed unresectable at first operative exploration. J Am Coll Surg. 2012;215(1):41–51; discussion 52. Epub 2012/05/23.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mark J. Truty M.D., M.Sc. .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Truty, M.J. (2016). The Role and Techniques of Vascular Resection. In: Katz, M., Ahmad, S. (eds) Multimodality Management of Borderline Resectable Pancreatic Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-22780-1_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-22780-1_13

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-22779-5

  • Online ISBN: 978-3-319-22780-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics